Hospitals that enrolled in the 340B program after its expansion in 2010 treated more commercially insured cancer patients with five commonly prescribed biologic oncology drugs and spent more on the drugs, a new JAMA study found.
The authors of
Category: Research/Reports
Ryan White Clinics for 340B Access yesterday criticized drug manufacturer Gilead Sciences for sponsoring a study that said it is unclear if patients of Ryan White clinics and other 340B grantee covered entities benefit from the drug margin these entities
…
The Medicare Payment Advisory Commission is sticking by its long-standing recommendation that Medicare should pay less for Part B drugs furnished by 340B hospitals.
“We continue to believe that this approach is appropriate, and the specific level of payment reduction
…
Drug manufacturers often observe that a growing share of their take from gross sales goes to middlemen and others in the form of rebates and discounts. A term has been coined to describe the phenomenon: the gross-to-net bubble (the difference
…
Nonprofit hospitals’ profits and cash reserves grew substantially between 2012 and 2019 without a corresponding rise in spending on charity care, a new study in the June issue of Health Affairs found.
The American Hospital Association quickly issued a rebuttal.
…
Rural hospitals that enroll in the 340B drug pricing program are more likely to initiate oncology services than those that do not participate, a study published online Monday in Health Affairs found.
“It’s estimated that around one in five rural
…
ASAP 340B, the group that drug manufacturers and community health centers formed to advance a joint 340B reform agenda, recently released a two-page explainer on how their plan would change the 340B patient definition. Under it, fewer drugs prescribed at
…
340B-eligible providers prescribe generic drugs at the same overall rate as non-340B providers, a study published in JAMA Health Forum found. “We found no evidence that 340B-eligible prescribers were systematically overprescribing brand-name drugs to generate revenue,” the authors said.
Health centers and other federal grantees’ 340B savings and how they use them need more scrutiny, as these covered entities account for a large chunk of total 340B drug sales and their margins are keeping pace with those of hospitals,
…Breaking News
HRSA and Prime Vendor Yank FAQs About 340B Use in Hospital Child Sites, and GAO Issues a New 340B Study
The U.S. Health Resources and Services Administration midday yesterday and the 340B prime vendor Apexus this morning, in connection with the end of the COVID-19 public health emergency late last night, withdrew mostly identical 340B program FAQs about use of
…